TABLE 2.
Donor number | Control | GITR | IL-15 | IL-15 + GITRa |
---|---|---|---|---|
1 | 28.9 | 55.04 | 57 | 63.45 |
2 | 16.02 | 14.33 | 28.12 | 46.3 |
3 | 27.85 | 32.47 | 33.6 | 48.6 |
4 | 42.5 | 46 | 50.1 | 63.1 |
5 | 18.87 | 8.56 | 9.53 | 13.85 |
6 | 65.7 | 67.1 | 71.9 | 78.4 |
7 | 54.49 | 77.09 | 54.4 | 81.69 |
8 | 34.61 | 72.19 | 44.2 | 88.64 |
9 | 50 | 52.58 | 66.3 | 75.63 |
10 | 36.7 | 35.3 | 39.2 | 41.5 |
11 | 25.66 | 23.72 | 33.7 | 40.6 |
12 | 41 | 45.5 | 43.7 | 51.7 |
13 | 62 | 55.28 | 69.9 | 74.7 |
14 | 56.3 | 49.2 | 37.3 | 40.9 |
Significant increase occurred in IL-15 plus anti-GITR treatment group compared with IL-15 treatment only (p < 0.01).